Skip to main
LIVN

Livanova (LIVN) Stock Forecast & Price Target

Livanova (LIVN) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 50%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

LivaNova's sales demonstrated a significant growth of 29%, reaching $803 million in 2024, with management projecting a continued upward trajectory towards $940-$955 million. The company is also expected to strengthen its market position in the neuromodulation sector, particularly with the aura6000, which has a projected market share increase from 9.0% to 14.9% between 2027 and 2029, corresponding to estimated sales growth from $120 million to $280 million. LivaNova’s robust revenue foundation, bolstered by its strategic focus on cardiopulmonary solutions and neuromodulation devices, provides a solid basis for a positive financial outlook.

Bears say

LivaNova's stock outlook is negatively impacted by anticipated revenue growth slowing to low-single digits due to ongoing challenges in its Neuromodulation and Cardiovascular segments. Additionally, the company is facing operating margin contraction and is projected to deliver earnings below consensus expectations, further compounding financial concerns. Risks to the forecast include the possibility of failing to secure FDA approval for new products, specifically the aura6000, and slower-than-expected growth in both Neuromodulation and Cardiopulmonary divisions.

Livanova (LIVN) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 50% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Livanova and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Livanova (LIVN) Forecast

Analysts have given Livanova (LIVN) a Buy based on their latest research and market trends.

According to 8 analysts, Livanova (LIVN) has a Buy consensus rating as of Jan 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $66.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $66.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Livanova (LIVN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.